AMA0076
drugOn this page
Also known as AMA-0076PHP-201PHP201Sovesudil
Summary
Ama0076 (CHEMBL3545073) is a phase-3 clinical-stage unknown targeting ROCK2; indicated across 4 conditions including ocular hypertension and glaucoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- Targets: 1 (ROCK2)
- Indications: 4 conditions
- Clinical trials: 5
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3545073 |
| Name | AMA0076 |
| Type | Unknown |
| Max phase | 3 |
Also known as: AMA-0076, Ama0076, PHP-201, PHP201, Sovesudil, AMA0076
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| ROCK2 | Rho associated coiled-coil containing protein kinase 2 | Inhibition | 8.29 | 1.1% | O75116 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): ROCK2.
Top Reactome pathways
32 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Developmental Biology | 1 | ROCK2 |
| Signal Transduction | 1 | ROCK2 |
| Disease | 1 | ROCK2 |
| Signaling by VEGF | 1 | ROCK2 |
| Signaling by Rho GTPases | 1 | ROCK2 |
| RHO GTPase Effectors | 1 | ROCK2 |
| EPH-Ephrin signaling | 1 | ROCK2 |
| Signaling by GPCR | 1 | ROCK2 |
| Semaphorin interactions | 1 | ROCK2 |
| GPCR downstream signalling | 1 | ROCK2 |
| EPHB-mediated forward signaling | 1 | ROCK2 |
| EPHA-mediated growth cone collapse | 1 | ROCK2 |
| Sema4D in semaphorin signaling | 1 | ROCK2 |
| G alpha (12/13) signalling events | 1 | ROCK2 |
| Sema4D induced cell migration and growth-cone collapse | 1 | ROCK2 |
| Axon guidance | 1 | ROCK2 |
| VEGFA-VEGFR2 Pathway | 1 | ROCK2 |
| RHO GTPases Activate ROCKs | 1 | ROCK2 |
| Infectious disease | 1 | ROCK2 |
| RHOA GTPase cycle | 1 | ROCK2 |
| Signaling by Receptor Tyrosine Kinases | 1 | ROCK2 |
| RHO GTPase cycle | 1 | ROCK2 |
| RHOB GTPase cycle | 1 | ROCK2 |
| RHOC GTPase cycle | 1 | ROCK2 |
| RHOH GTPase cycle | 1 | ROCK2 |
| RHOBTB1 GTPase cycle | 1 | ROCK2 |
| Nervous system development | 1 | ROCK2 |
| Potential therapeutics for SARS | 1 | ROCK2 |
| SARS-CoV Infections | 1 | ROCK2 |
| RHOBTB GTPase Cycle | 1 | ROCK2 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| mitotic cytokinesis | 1 |
| epithelial to mesenchymal transition | 1 |
| response to ischemia | 1 |
| aortic valve morphogenesis | 1 |
| protein phosphorylation | 1 |
| smooth muscle contraction | 1 |
| Rho protein signal transduction | 1 |
| positive regulation of cardiac muscle hypertrophy | 1 |
| positive regulation of gene expression | 1 |
| negative regulation of gene expression | 1 |
| positive regulation of centrosome duplication | 1 |
| negative regulation of angiogenesis | 1 |
| actin cytoskeleton organization | 1 |
| regulation of cell adhesion | 1 |
| positive regulation of cell migration | 1 |
Indications & clinical
Indications
4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| ocular hypertension | 2 | MONDO:0006875 | EFO:1001069 |
| glaucoma | 2 | MONDO:0005041 | MONDO:0005041 |
| eye disorder | 2 | MONDO:0005328 | EFO:0003966 |
| low tension glaucoma | 2 | MONDO:0006837 | EFO:1001022 |
Clinical trials
Total trials: 5.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 3 |
| PHASE1 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01693315 | PHASE2 | COMPLETED | Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma |
| NCT02136940 | PHASE2 | COMPLETED | Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension |
| NCT03106532 | PHASE2 | COMPLETED | Evaluation of PHP-201 Ophthalmic Solution in Patients With Normal Tension Glaucoma |
| NCT02003547 | PHASE1 | COMPLETED | A Single Centre Study to Evaluate 3 Ophthalmic Formulations in Healthy Subjects |
| NCT03586908 | PHASE1 | COMPLETED | PK/PD, Safety and Tolerability of PHP-201 Topical Eye Drop in Korean and Japanese Healthy Subjects |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
49 molecules share ≥1 primary target. Top 49 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| BELUMOSUDIL | ChEMBL + PubChem | Phase 4 (approved) | ROCK2 |
| CRIZOTINIB | ChEMBL + PubChem | Phase 4 (approved) | ROCK2 |
| BARICITINIB | ChEMBL | Phase 4 (approved) | ROCK2 |
| BOSUTINIB | ChEMBL | Phase 4 (approved) | ROCK2 |
| CAPIVASERTIB | ChEMBL | Phase 4 (approved) | ROCK2 |
| CERITINIB | ChEMBL | Phase 4 (approved) | ROCK2 |
| FEDRATINIB | ChEMBL | Phase 4 (approved) | ROCK2 |
| MIDOSTAURIN | ChEMBL | Phase 4 (approved) | ROCK2 |
| MOMELOTINIB | ChEMBL | Phase 4 (approved) | ROCK2 |
| NETARSUDIL | ChEMBL | Phase 4 (approved) | ROCK2 |
| PALBOCICLIB | ChEMBL | Phase 4 (approved) | ROCK2 |
| RUXOLITINIB | ChEMBL | Phase 4 (approved) | ROCK2 |
| SUNITINIB | ChEMBL | Phase 4 (approved) | ROCK2 |
| TOFACITINIB | ChEMBL | Phase 4 (approved) | ROCK2 |
| UPADACITINIB | ChEMBL | Phase 4 (approved) | ROCK2 |
| VANDETANIB | ChEMBL | Phase 4 (approved) | ROCK2 |
| AFURESERTIB | ChEMBL | Phase 3 | ROCK2 |
| ALVOCIDIB | ChEMBL | Phase 3 | ROCK2 |
| DOVITINIB | ChEMBL | Phase 3 | ROCK2 |
| FASUDIL | ChEMBL | Phase 3 | ROCK2 |
| LESTAURTINIB | ChEMBL | Phase 3 | ROCK2 |
| LINIFANIB | ChEMBL | Phase 3 | ROCK2 |
| RIPASUDIL | ChEMBL | Phase 3 | ROCK2 |
| CENISERTIB | ChEMBL | Phase 2 | ROCK2 |
| DECERNOTINIB | ChEMBL | Phase 2 | ROCK2 |
| FORETINIB | ChEMBL | Phase 2 | ROCK2 |
| ILORASERTIB | ChEMBL | Phase 2 | ROCK2 |
| LAUROGUADINE | ChEMBL | Phase 2 | ROCK2 |
| PH-797804 | ChEMBL | Phase 2 | ROCK2 |
| R-406 | ChEMBL | Phase 2 | ROCK2 |
| RG-547 | ChEMBL | Phase 2 | ROCK2 |
| RIPASUDIL HYDROCHLORIDE DIHYDRATE | ChEMBL | Phase 2 | ROCK2 |
| SAR-407899 FREE BASE | ChEMBL | Phase 2 | ROCK2 |
| SU-014813 | ChEMBL | Phase 2 | ROCK2 |
| UCN-01 | ChEMBL | Phase 2 | ROCK2 |
| UPROSERTIB | ChEMBL | Phase 2 | ROCK2 |
| VEROSUDIL | ChEMBL | Phase 2 | ROCK2 |
| ZOTIRACICLIB | ChEMBL | Phase 2 | ROCK2 |
| Afatinib | PubChem | Approved | ROCK2 |
| Belzutifan | PubChem | Approved | ROCK2 |
| Binimetinib | PubChem | Approved | ROCK2 |
| dacomitinib | PubChem | Approved | ROCK2 |
| Fostamatinib | PubChem | Approved | ROCK2 |
| Gefitinib | PubChem | Approved | ROCK2 |
| Idelalisib | PubChem | Approved | ROCK2 |
| Pazopanib | PubChem | Approved | ROCK2 |
| regorafenib | PubChem | Approved | ROCK2 |
| Selumetinib | PubChem | Approved | ROCK2 |
| Trametinib | PubChem | Approved | ROCK2 |
Related Atlas pages
- Genes: ROCK2
- Drugs: Belumosudil, Crizotinib, Baricitinib, Bosutinib, Capivasertib, Ceritinib, Fedratinib, Midostaurin, Momelotinib, Netarsudil, Palbociclib, Ruxolitinib, Sunitinib, Tofacitinib, Upadacitinib, Vandetanib, Afuresertib, Alvocidib, Dovitinib, Fasudil, Lestaurtinib, Linifanib, Ripasudil, Afatinib, Belzutifan, Binimetinib, dacomitinib, Fostamatinib, Gefitinib, Idelalisib, Pazopanib, regorafenib, Selumetinib, Trametinib